SULZER
Sulzer’s newly developed Blueline cartridge system is designed specifically for the application of highly viscous materials, with a view to enhancing end users’ productivity. Blueline delivers a threefold increase in dispensing rates compared with conventional cartridge systems. It is compatible with commonly used dispensers and will be unveiled at the JEC World 2017 exhibition in Paris.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170314005752/en/
Sulzer Mixpac AG – a subsidiary of Sulzer Ltd., a global leader in the manufacture and supply of liquid application and mixing technology products and services – will showcase its innovative new Blueline cartridge system at JEC World 2017 in Paris.
Dispensing rates up to three times higher
Highly viscous materials push existing cartridge systems to their limits in terms of the achievable dispensing rate. Previously, users would have to make do with small quantities of such materials or switch to considerably more complex mechanical processing of adhesives. Available with 2:1 and 10:1 mixing ratios, the Blueline cartridge system opens up a host of new possibilities.
Applications in aircraft and vehicle construction, general industry and the building sector
Marco Frei, Head Sales Industry EMIRA at Sulzer Mixpac AG, explains: “Blueline extends the range of possible applications for cartridges , allowing end users to boost productivity. Compared with existing systems, it offers considerably higher dispensing rates when applying highly viscous materials. The large cross-sections of the outlets combined with new, optimised mixing geometry increases dispensing rates up to threefold compared with currently available cartridge systems – and all this with the same dispensing force. The interface design features separate outlets from the cartridge to the mixer, removing the risk of unintentional mixing and clogging of the cartridge outlet by material components. This translates into clean and reliable processing of two-component materials.”
Quick, safe and clean processing of sensitive 2-K materials
Honeycomb core and edging filler are applied in two-component (2-K) form in sectors such as aircraft construction. These materials have densities of less than 1g/ml and are formed by adding hollow plastic or glass spheres, which helps to reduce weight. When processing such materials, high pressure and high shear rates cause these spheres to burst, making them unusable. In addition, these materials are also highly viscous, and in some cases there are differences in compressibility between the two components. For these reasons, the options for processing such materials using cartridge systems were previously extremely limited. The new Blueline system changes all this – it opens up a host of totally new possibilities, allowing for the rapid, safe and clean processing of sensitive 2-K materials with the help of cartridge systems.
JEC in Paris
The JEC trade fair is the world’s largest composites exhibition, making it the ideal platform for Sulzer Mixpac to introduce its Blueline system and showcase its entire range of dispensers and cartridge-based application systems.
Blueline – key facts
- For highly viscous materials that are difficult to apply
- For high dispensing rates (threefold increase in dispensing quantity)
- For materials sensitive to pressure and shearing
- Compatible with commonly used MIXPAC dispensers
Sulzer Mixpac at JEC World 2017
Paris Nord Villepinte Exhibition Centre, hall 6, stand A62
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005752/en/
Contact:
Sulzer
Gerald Fleisch
Head of Marketing Sulzer Mixpac, Sulzer
Mixpac Ltd
Tel: +41 (0)81 772 2164
gerald.fleisch@sulzer.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 14:00:00 CET | Press release
Prospective, randomized controlled trial compares novel femtosecond laser procedure to selective laser trabeculoplasty (SLT), advancing path to US commercialization ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous e
Winchester Interconnect Launches LiteSPEed™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 14:00:00 CET | Press release
Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has
Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 14:00:00 CET | Press release
Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa
Adva Network Security achieves BSI approval for PQC-encrypted edge networking device3.12.2025 14:00:00 CET | Press release
News summary: Critical infrastructure, defense and governments need quantum-safe encryption at the edge to neutralize ‘harvest-now, decrypt-later’ risks FSP 150-XG118Pro (CSH) delivers quantum-safe encryption via software update, enabling seamless upgrades with no hardware changes BSI approval confirms the device’s compliance for government and defense use Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infra
Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 14:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom